SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus by Andersson, Monique I et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SARS-CoV-2 RNA detected in blood products from patients with
COVID-19 is not associated with infectious virus
Citation for published version:
Andersson, MI, Arancibia-Carcamo, CV, Auckland, K, Baillie, JK, Barnes, E, Beneke, T, Bibi, S, Brooks, T,
Carroll, M, Crook, D, Dingle, K, Dold, C, Downs, LO, Dunn, L, Eyre, DW, Gilbert Jaramillo, J, Harvala, H,
Hoosdally, S, Ijaz, S, James, T, James, W, Jeffery, K, Justice, A, Klenerman, P, Knight, JC, Knight, M, Liu,
X, Lumley, SF, Matthews, PC, McNaughton, AL, Mentzer, AJ, Mongkolsapaya, J, Oakley, S, Oliveira, MS,
Peto, T, Ploeg, RJ, Ratcliff, J, Robbins, MJ, Roberts, DJ, Rudkin, J, Russell, RA, Screaton, G, Semple, MG,
Skelly, D, Simmonds, P, Stoesser, N, Turtle, L, Wareing, S & Zambon, M 2020, 'SARS-CoV-2 RNA
detected in blood products from patients with COVID-19 is not associated with infectious virus', Wellcome
Open Research , vol. 5, pp. 181. https://doi.org/10.12688/wellcomeopenres.16002.2
Digital Object Identifier (DOI):
10.12688/wellcomeopenres.16002.2
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Wellcome Open Research
Publisher Rights Statement:
Copyright: © 2020 Andersson MI et al. This is an open access article distributed under the terms of the Creative
Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 04. Jan. 2021
RESEARCH ARTICLE
   SARS-CoV-2 RNA detected in blood products from 
patients with COVID-19 is not associated with infectious virus 
[version 2; peer review: 2 approved]
Monique I. Andersson 1, Carolina V. Arancibia-Carcamo2-4, Kathryn Auckland3, 
J. Kenneth Baillie5, Eleanor Barnes1,2,4, Tom Beneke 6, Sagida Bibi7, Tim Brooks8, 
Miles Carroll8, Derrick Crook 1,3,4, Kate Dingle 3, Christina Dold7, 
Louise O. Downs 1, Laura Dunn1, David W. Eyre1,3,4,9, Javier Gilbert Jaramillo 6, 
Heli Harvala10,11, Sarah Hoosdally3, Samreen Ijaz12, Tim James1, William James 6, 
Katie Jeffery 1, Anita Justice1, Paul Klenerman 1-3, Julian C. Knight1,3, 
Michael Knight 6, Xu Liu 6, Sheila F. Lumley1,3, Philippa C. Matthews 1,3,4, 
Anna L. McNaughton 3, Alexander J. Mentzer 1,3, Juthathip Mongkolsapaya3, 
Sarah Oakley1, Marta S. Oliveira13,14, Timothy Peto1,3,4, Rutger J. Ploeg 14, 
Jeremy Ratcliff 3, Melanie J. Robbins15, David J. Roberts13, Justine Rudkin 9,16, 
Rebecca A. Russell6, Gavin Screaton3, Malcolm G. Semple 17, Donal Skelly 1,3, 
Peter Simmonds 1,3, Nicole Stoesser1,3, Lance Turtle 17, Susan Wareing1, 
Maria Zambon 12
1Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
2Translational Gastroenterology Unit, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
3Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
4NIHR Oxford Biomedical Research Centre (BRC), John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
5Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian, EH25 9RG, UK 
6Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK 
7Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
8Porton Down, Public Health England, Manor Farm Road, Porton Down, Salisbury, SP4 0JG, UK 
9Big Data Institute, Roosevelt Drive, Old Road Campus, Headington, Oxford, OX3 7LF, UK 
10NHS Blood and Transfusion, 26 Margaret St, Marylebone, London, W1W 8NB, UK 
11University College London, Gower St, Bloomsbury, London, WC1E 6BT, UK 
12Public Health England, 61 Colindale Ave, London, NW9 5EQ, UK 
13NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
14Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK 
15Component Development Laboratory, NHS Blood and Transplant, Cambridge Donor Centre, Cambridge, CB2 0PT, UK 
16Nuffield Department of Population Health, University Oxford Richard Doll Building, Old Road Campus, Headington, Oxford, OX3 
7LF, UK 
17NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of 
Liverpool, Liverpool, L69 3BX, UK 
First published: 29 Jul 2020, 5:181  
https://doi.org/10.12688/wellcomeopenres.16002.1
 
Page 1 of 21
Wellcome Open Research 2020, 5:181 Last updated: 25 NOV 2020
Latest published: 12 Oct 2020, 5:181  
https://doi.org/10.12688/wellcomeopenres.16002.2
v2
Abstract 
Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause 
of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory 
samples. SARS-CoV-2 RNA has also been detected in other sample 
types, but there is limited understanding of the clinical or laboratory 
significance of its detection in blood. 
Methods: We undertook a systematic literature review to assimilate 
the evidence for the frequency of vRNA in blood, and to identify 
associated clinical characteristics. We performed RT-PCR in serum 
samples from a UK clinical cohort of acute and convalescent COVID-19 
cases (n=212), together with convalescent plasma samples collected 
by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To 
determine whether PCR-positive blood samples could pose an 
infection risk, we attempted virus isolation from a subset of RNA-
positive samples. 
Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA 
in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). 
Among serum samples from our clinical cohort, 27/212 (12.7%) had 
SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in 
samples up to day 20 post symptom onset, and was associated with 
more severe disease (multivariable odds ratio 7.5). Across all samples 
collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) 
had vRNA detected. Among our PCR-positive samples, cycle threshold 
(ct) values were high (range 33.5-44.8), suggesting low vRNA copy 
numbers. PCR-positive sera inoculated into cell culture did not 
produce any cytopathic effect or yield an increase in detectable SARS-
CoV-2 RNA. There was a relationship between RT-PCR negativity and 
the presence of total SARS-CoV-2 antibody (p=0.02). 
Conclusions: vRNA was detectable at low viral loads in a minority of 
serum samples collected in acute infection, but was not associated 
with infectious SARS-CoV-2 (within the limitations of the assays used). 
This work helps to inform biosafety precautions for handling blood 
products from patients with current or previous COVID-19.
Keywords 
COVID-19, SARS-CoV-2, viral load, viraemia, RNA, blood, biomarker, 
laboratory safety
 
This article is included in the Coronavirus 
(COVID-19) collection.
Open Peer Review
Reviewer Status   
Invited Reviewers
1 2
version 2
(revision)
12 Oct 2020
report report
version 1
29 Jul 2020 report
William L. Irving , Nottingham University 
Hospitals NHS Trust, Nottingham, UK
1. 
Le Sun, AnyGo Technology, Beijing, China 
AbMax Biotechnology, Beijing, China
2. 
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 2 of 21
Wellcome Open Research 2020, 5:181 Last updated: 25 NOV 2020
Corresponding author: Philippa C. Matthews (philippa.matthews@ndm.ox.ac.uk)
Author roles: Andersson MI: Supervision; Arancibia-Carcamo CV: Resources; Auckland K: Investigation; Baillie JK: Resources; Barnes 
E: Supervision; Beneke T: Formal Analysis, Investigation, Methodology; Bibi S: Investigation; Brooks T: Supervision; Carroll M: 
Resources, Supervision; Crook D: Conceptualization, Project Administration, Supervision, Writing – Review & Editing; Dingle K: 
Investigation; Dold C: Investigation; Downs LO: Investigation, Writing – Review & Editing; Dunn L: Investigation; Eyre DW: 
Conceptualization, Data Curation, Formal Analysis, Writing – Review & Editing; Gilbert Jaramillo J: Investigation; Harvala H: Data 
Curation, Resources, Supervision, Writing – Review & Editing; Hoosdally S: Project Administration; Ijaz S: Investigation; James T: 
Methodology, Supervision, Writing – Review & Editing; James W: Conceptualization, Formal Analysis, Methodology, Writing – Review & 
Editing; Jeffery K: Supervision; Justice A: Investigation; Klenerman P: Project Administration, Supervision; Knight JC: Investigation, 
Project Administration, Supervision; Knight M: Investigation; Liu X: Investigation; Lumley SF: Investigation; Matthews PC: 
Conceptualization, Data Curation, Formal Analysis, Project Administration, Supervision, Writing – Original Draft Preparation; 
McNaughton AL: Investigation, Writing – Review & Editing; Mentzer AJ: Conceptualization, Investigation, Project Administration; 
Mongkolsapaya J: Investigation; Oakley S: Resources; Oliveira MS: Investigation; Peto T: Conceptualization, Supervision; Ploeg RJ: 
Project Administration; Ratcliff J: Investigation; Robbins MJ: Data Curation; Roberts DJ: Project Administration, Resources; Rudkin J: 
Investigation; Russell RA: Investigation; Screaton G: Supervision; Semple MG: Investigation, Project Administration, Supervision; Skelly 
D: Investigation; Simmonds P: Methodology, Supervision, Writing – Review & Editing; Stoesser N: Conceptualization, Project 
Administration, Writing – Review & Editing; Turtle L: Investigation, Project Administration; Wareing S: Investigation; Zambon M: 
Methodology, Writing – Review & Editing
Competing interests: DWE has received personal fees from Gilead, outside the submitted work.
Grant information: This work was supported by the Wellcome Trust through an Investigators award to JK [204969], a DFID-Wellcome 
Epidemic Preparedness Grant [215091], and Fellowship Grants to PCM and LT [110110 and 205228]. A full list of all funding supporting 
the current study is provided below: ● National Institute for Health Research [CO-CIN-01], ● Medical Research Council [MC_PC_19059], 
● National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University 
of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the 
University of Oxford [NIHR award 200907], ● The Bill and Melinda Gates Foundation [OPP1209135], ● Liverpool Experimental Cancer 
Medicine Centre (infrastructure support) [ref: C18616/A25153]. ● TB, CVA-C, PCM, PK and DC received funding from NIHR Oxford 
Biomedical Research Centre. ● DWE is a Robertson Foundation Fellow. ● EB is an NIHR Senior Investigator. The views expressed in this 
article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.  
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2020 Andersson MI et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Andersson MI, Arancibia-Carcamo CV, Auckland K et al. SARS-CoV-2 RNA detected in blood products from 
patients with COVID-19 is not associated with infectious virus [version 2; peer review: 2 approved] Wellcome Open Research 2020, 
5:181 https://doi.org/10.12688/wellcomeopenres.16002.2
First published: 29 Jul 2020, 5:181 https://doi.org/10.12688/wellcomeopenres.16002.1 
 
Page 3 of 21
Wellcome Open Research 2020, 5:181 Last updated: 25 NOV 2020
Background
Since January 2020, the SARS-CoV-2 virus has caused a glo-
bal pandemic of COVID-19, challenging hospitals and labora-
tory services worldwide1. Diagnosis of infection has largely been 
based on RT-PCR amplification of viral nucleic acid from the 
upper respiratory tract (nose/throat) swabs2. However, detec-
tion of viral RNA (vRNA) has also been reported in blood, 
serum and plasma from clinical small case series (e.g. 3,4). The 
frequency and quantification of SARS-CoV-2 RNA in blood 
fractions, and the significance of blood as a transmission 
route remains unknown.
Understanding the clinical contexts within which SARS-CoV-2 
RNA can be detected in blood is important to determine the 
extent to which PCR-positive blood, plasma or serum could have 
impact as a clinically useful biomarker of disease severity or prog-
nosis. Furthermore, there is an urgent need to consider whether 
the detection of viral RNA in blood samples reflects the pres-
ence of infectious virus, as this has important safety implications 
for clinicians and laboratory personnel engaged in both routine 
laboratory testing, as well as SARS-CoV-2-specific pipelines 
such as serology5,6.
Different organisations have made varying recommendations for 
the laboratory handling of samples from patients with suspected 
or confirmed SARS-CoV-2, but these have had to be developed 
quickly in the face of little experience or data, and rely on the 
presence of viral RNA in samples as an imperfect surrogate for 
live virus. Laboratory protocols seeking to reduce the biobur-
den of SARS-CoV-2 in clinical samples suggest either chemical 
inactivation (e.g. with sodium-dodecyl-sulfate, Triton-X100, 
and/or guanidinium thiocyanate-lysis buffers), alone or in com-
bination with heating protocols that vary from 30°C up to as 
high as 92°C for 15 minutes7. These approaches add processing 
time, may require additional laboratory reagents, and are also 
potentially associated with a loss of sensitivity in any downstream 
analysis, particularly pertinent for serological assays. Previ-
ous reports suggest that heat inactivation may be particularly 
detrimental to the sensitivity of antibody detection8.
An alternative to chemical or heat inactivation is to undertake 
all sample handling in a biosafety (containment) level 3 (BSL3) 
facility, but this is expensive, requires specialist staff train-
ing, substantially reduces the number of samples that can be 
processed, and is completely inaccessible in many settings. 
There is a lack of consensus about appropriate biosafety 
precautions, and escalation to BSL3 may be based on concerns 
about risks associated with viraemic samples even when the risk 
of aerosol generation is low, and there are no data to suggest a 
risk of blood-borne transmission to laboratory staff.
Here we assimilate the peer-reviewed literature describing the 
presence of SARS CoV-2 RNA in human blood, with the aim 
of providing a pooled dataset to provide improved insights into 
the causes and correlates of RNA-aemia. We then present our 
own investigation of the frequency and determinants of vRNA 
detection in blood using 424 samples collected from acutely 
infected and convalescent patients infected with SARS-CoV-2. 
We attempted in vitro isolation of the virus from viraemic 
samples in order to determine whether RNA detection is a 
marker of infectious virus. Together, these data may help to 
determine the significance of viral RNA in blood, and can 
contribute to the development of consistent and evidence-based 
laboratory protocols.
Methods
Terminology and definitions
•    Blood: we have used the term blood to refer to whole 
blood, serum or plasma when there is not a clear distinc-
tion in existing pre-published data, although we recognise 
that there may be differences in the sensitivity of viral 
detection between whole blood and blood fractions.
•    Serum: in the work undertaken here, we refer specifi-
cally to serum, as this blood fraction was consistently used 
across our experiments.
•    RNA-aemia: we have used this term to describe the 
presence of viral RNA, above the technical limits of 
detection of RT-PCR assays, in blood, serum or plasma. 
The alternative term, ‘viraemia’, suggests the presence 
of whole virus in blood. Since we have not demonstrated 
the presence of replication-competent (infectious) SARS-
CoV-2 in the blood compartment, we have elected to use 
the more conservative description of RNA-aemia (which 
may or not indicate viraemia). 
Systematic literature review
We searched PubMed, Web of Science, MedRxiv and Google 
between 7th-11th May 2020, using the search terms (“SARS-
CoV-2” OR “COVID” OR “2019-nCoV” OR “COVID-19” OR 
“2019 NCOV” or “SARS COV 2” or “2019NCOV” or “2019-
nCoV” or “2019 novel coronavirus”) AND (“qPCR” OR “RT-
PCR” OR “PCR” OR “VIRAL LOAD” OR “RNAaemia” OR 
“RNAemia” OR “viraemia” OR “viremia” OR “RNA-aemia” OR 
“RNA-emia”) AND (“BLOOD” OR “PLASMA” OR “SERUM”). 
We excluded animal studies. We did not make exclusions 
on the basis of language, but two papers not in English were 
ruled out because they did not contain details of vRNA detection 
that we required. Each study was reviewed by at least two 
independent reviewers. A PRISMA flow chart is presented, 
showing identification of 28 relevant studies (Figure 1; Extended 
Data Table 19). We collected information on the prevalence of 
vRNA detection in blood, serum or plasma, noting whether this 
attribute was correlated with clinical or laboratory phenotypes 
of disease, and recording cycle threshold (Ct) values when these 
          Amendments from Version 1
The amended version of this article includes new data reporting total 
antibody titres measured using the Siemens Attelica immmunoassay 
on a subset of our SARS-CoV-2-positive samples. We show a 
relationship between antibody-negative status and the presence of 
RNA-aemia. However, absolute antibody titres were not statistically 
different in the samples that were RT-PCR positive vs negative, and the 
lack of cytopathic effect in vitro was not dependent on the presence 
of antibody. The additional data are supported by small changes in 
the abstract, methods, results and discussion.
Any further responses from the reviewers can be found at 
the end of the article
REVISED
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Figure 1. PRISMA flow diagram showing number of abstracts identified through a systematic literature review, rejections (with 
reasons), and final number of studies included in the analysis.
were reported. Data were collated in Microsoft Excel v16.31. 
To allow appraisal of quality and identification of bias, we 
recorded the number of  participants in each study, the location 
and nature of the study cohort, and (where available) the severity 
of illness and the  timing of sample collection relative to symp-
toms or PCR- diagnosis. To reduce bias in the meta-analysis, we 
removed one study each of uninfected (healthy) donors and 
convalescent  individuals, and four studies with <5 participants, 
taking the final number of studies analysed to 22 
(Figure 2).
Cohorts and sample selection
The origin of serum samples, together with supporting meta-
data, are available in Underlying Data File 19. We collected 212 
serum samples through the microbiology department at Oxford 
University Hospitals NHS Foundation Trust (OUH NHSFT), 
comprising adults with SARS-CoV-2 infection confirmed by a 
clinical diagnostic microbiology laboratory using RT-PCR on a 
respiratory swab. These were derived from three groups as 
follows:
(i)    Hospital in-patients, n=139 samples from 94 partici-
pants; these were collected from individuals admitted to 
OUH NHSFT, a tertiary referral centre in the South East 
of England, for treatment of COVID-19. Samples were 
collected between 1–5 days following admission to hos-
pital or intensive care (whichever came later), a median 
of 8 days following symptom onset (range 1-37 days).
(ii)    Convalescent healthcare workers, n=41 samples from 
41 participants; these were collected from healthcare 
workers from OUH NHSFT, following a period of 
≥ 7 days absence from work following a diagnosis of 
COVID-19, a median of 12 days following symptom 
onset (range 7–17 days).
(iii)    Convalescent patients, n=32 samples from 32 par-
ticipants; these were collected from patients presenting 
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to OUH NHS FT followed up in the community, a 
median of 42 days following onset of COVID-19 symp-
toms (range 31–62 days).
Additional samples were collected through NHS Blood and 
Transplant (NHSBT), as follows:
(vi)    Convalescent plasma donors, n=142 samples from 
142 volunteer plasma donors, ≥28 days from recov-
ery of symptoms. Retrospective confirmation of 
COVID-19 infection was based on a EuroImmun IgG 
antibody titre (threshold ratio ≥1.1, based on the 
manufacturer’s instructions, Underlying data table 1).
(v)    Healthy pre-pandemic controls, n=5 samples from 
5 independent healthy volunteer donors, collected prior 
to December 2019.
In groups (i)–(iii) >1 sample was obtained from 45 individuals, 
so our clinical dataset overall represents 167 unique individuals 
with COVID-19. Among these 167 individuals, we classified 
severity of illness as asymptomatic, mild, severe, or critical 
based on standard WHO criteria10. All serum samples were frozen 
in 0.5ml aliquots at -20℃.
RT-PCR on serum samples
Following nucleic acid extraction, we used reverse transcription 
(RT)-PCR to amplify SARS-CoV targets from serum samples. 
PCR primer sequences are available in a supporting on-line file set9. 
Due to different pathways for patient recruitment and 
sample processing, PCR protocols varied by cohort, as follows:
•    Samples from acute hospital admissions and convales-
cent health care workers were processed by the OUH 
NHSFT clinical microbiology laboratory (UKAS accred-
ited to ISO 15189:2012), using a Quiagen Symphony 
Rotorgene protocol with an RNA-dependent RNA 
polymerase (RdRP) gene target, validated by Public 
Health England (PHE) for use on respiratory samples11,12. 
Figure 2. Prevalence of SARS-CoV-2 RNA in serum / plasma / whole blood samples from a systematic literature review. Point 
prevalence indicated for each study with confidence intervals showing citation and number of samples represented (Table 1).
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Table 1. Frequency of SARS-CoV-2 RNA in human blood and blood products based on a systematic literature review. Full 
metadata are presented in Extended Data File 1, available online9.
Citation Setting Frequency and characteristics of SARS-CoV-2 RNA
ACUTE COVID-19 INFECTION
Wang et al., JAMA4 n=205 patients with COVID-19; Hubei and 
Shandong provinces and Beijing, China
   •   Blood: 3/307 samples RNA positive collected from 205 
patients (0.98%); mean Ct 34-35
   •   No difference in Ct values between blood, stool, and 
respiratory samples
Zhang et al., Emerging 
Microbes & Infections13
n=178; Wuhan pulmonary hospital, China    •  Whole blood: 6/178 (3.4%) PCR positive; Ct 30-32 
   •  Serum: 3/178 (1.7%) PCR positive; Ct 24-33 
   •   None of the patients with viral RNA detected in blood had 
positive respiratory swabs
Lescure et al., Lancet 
Inf. Dis.14
n= 5, hospital patients, France    •  Plasma: 1/5 (20%) PCR positive; Ct >35 
   •  Latest positive 12 days after symptom onset. 
   •  The patient with vRNA-aemia was the most severely ill.
Duan et al., PNAS15 n= 10, severe COVID19 patients, Wuhan, 
China
   •  Serum: 7/10 (70%) PCR positive; Ct 34-38
Chen et al., CID16 n=48, General Hospital of Central Theater 
Command, PLA, Wuhan, China
   •  Serum: 5/48 (10%) PCR positive 
   •   RNAaemia only in the critically ill group (but 12 critically ill 
patients had no RNA-aemia)
   •  RNA-aemia associated with elevated IL-6
Chen et al., Emerg 
Microbes Infect.17
n=57, Guangzhou Eighth People’s Hospital, 
China
   •  Serum: 6/57 (11%) PCR positive; Ct 32-41 
   •  RNA-aemia associated with severe symptoms
Fang et al., J. Infect.18 n=32, Central Hospital of Xiangtan, China    •   Blood: 7/8 (88%) PCR positive in ICU patients and 16/24 
(67%) in non-ICU patients.
Han et al., CID19 n=2, Seoul Metropolitan Government-
Seoul National University, Korea
   •  Mother and 27 day old infant 
   •   Plasma: RNA detected in infant up to day 10, mother’s 
plasma negative
Huang et al., Lancet20 n=41, hospitalised patients, Jin Yin-tan 
Hospital, Wuhan, China
   •  Plasma: 6/41 (15%) PCR positive 
   •   No difference in ICU admissions between patients with and 
without RNA-aemia.
Yu et al., CID21 n=4, Beijing Ditan Hospital, Capital Medical 
University, Beijing, China
   •  Blood: 0/4 (0%) PCR positive
Young et al., JAMA22 n= 18, hospitalized patients, Singapore    •  Blood: 1/12 (8%) PCR positive
Xie et al., Int J Inf Dis.23 n=9, Sichuan Provincial People’s Hospital 
and Sichuan Mianyang 404 Hospital, 
Chengdu, China
   •  Blood: 0/9 (0%) PCR positive
Wu et al.,Travel Med Inf 
Dis.24
n=132, The East Section of Renmin 
Hospital of Wuhan University, China
   •  Blood: 4/132 (3.03%) PCR positive
Cai et al., CID25 n=5, Childrens’ hospital, Shanghai    •  Serum: 0/5 PCR positive within 2-3 days of symptom onset
Zheng et al. BMJ3 n= 96 admitted patients Zhejiang province, 
China
   •   Serum: 39/96 (41%) overall (6/22 (27%) in mild cases, and 
33/74 (45%) in severe case)
   •  No difference in viral load between mild and severe cases 
   •   Serum had the lowest viral load compared with stool and 
respiratory samples.
Wolfel et al., Nature26 n=9, hospitalised, Munich, Germany    •  Serum: 0/9 (0%) PCR positive
Kujawski et al., Nature 
Medicine27
n=11, hospitalised patients, USA    •  Serum: 1/11 (9%) PCR positive 
   •   Detection of RNA in serum associated with clinical 
deterioration
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We used the QIAgen OBL complex 200 extraction 
method, using QIAsymphony DSP virus/pathogen mini kit 
(Qiagen 937036), adding 200µl of serum sample to 430µl 
QIAsymphony complex off-board lysis buffer (Internal 
Control MS2 RNA, Sigma-Aldrich 10165948001 (0.5µl); 
Molecular grade water Fisher Scientific 10245203 (1.5µl); 
RNA carrier, Qiagen 1017647 (9µl); AVE, Qiagen (109µl); 
PK, Qiagen 19133 (20µl); ATL, Qiagen 157054504 
(100µl); ACL, Qiagen 160030311 (190µl)) and eluting into 
60µl. Cycling conditions were 55°C for 10 minutes; 94°C 
for 3 minutes; 45 cycles of 94°C 15 seconds; 58°C for 
30 seconds. A report of Ct values, including positive con-
trol on each run, was generated by Rotor-Gene Q series 
software 2.3.1.
•    For convalescent OUH NHSFT patients, a nested PCR 
was undertaken using newly developed PCR primers at 
the Medawar Building for Pathogen Research, Oxford, 
targeting the RNA-dependent RNA polymerase (RdRp) 
gene of SARS-CoV-239. For the first round amplification, 
we generated a 25 µL reaction mix (5 µL RNA extract; 
12.5 µL 2X Quantitect Probe RT-PCR Master Mix 
(Qiagen 204343); 0.5 µL RT mix from the kit; 5 µL 5X 
1st-round primer mix (IDT); 2 µL PCR-grade water). PCR 
conditions: 50°C for 30 minutes; 95°C for 15 minutes; 
40 cycles of 95°C for 15 seconds; 55°C for 30 seconds; 
68°C for 1 minute; 68°C for 5 minutes. For the second 
round amplification, we generated a 25 µL reaction mix 
(1 µL of the first round product; 5 µL 5X GoTaq Green 
Master Mix (Promega M7841); 0.125 µL 5u/µL GoTaq 
G2 polymerase (Promega M7841); 2 µL 2.5 mM 
dNTP mix (Stratech NU-1020S-JEN-200ul); 5 µL 2nd-
round 5X primer mix (IDT); 11.875 µL PCR-grade 
water). PCR conditions: 95°C for 5 minutes, 40 cycles of 
95°C for 30 s, 55°C for 30 seconds, 72°C for 1 minute, 
final extension of 72°C for 5 minutes. The presence of 
SARS-CoV-2 RNA was confirmed through visualization of 
the PCR product via UV-Vis agarose gel electrophoresis. 
Citation Setting Frequency and characteristics of SARS-CoV-2 RNA
Peng L et al., J Med 
Virology28
n=9, hospitalised patients, Sun Yat‐sen 
University, China
   •  Whole blood: 2/9 PCR positive
Corman VM et al., 
Transfusion29
n=18, range of patients, Germany    •   Serum: 1/18 PCR positive, in patient with ARDS needing 
mechanical ventilation.
   •  SARS-CoV-2 present at 179 copies/ml
Song et al., MedRxiv30 n=1, China    •  Plasma: 0/1 positive
Lu et al., MedRxiv31 n=6, hospitalised patients,. Jiangsu, China.    •  Serum: 0/6 positive
Mancuso et al. 
MedRxiv32
n=22 (10 severe disease, 12 mild disease), 
Milan, Italy
   •   Plasma: 6/10 RNA positive in severe group (60%) and 2/12 
(1.6%) in the mild group.
Hogan et al., MedRxiv33 n=85, California, USA    •  Plasma: 28/85 detectable RNA 
   •   Median Ct value 37.5 (compared with 27.1 for 
nasopharyngeal aspirate)
   •   Those with RNA-aemia were older and more likely to go to 
ICU and need mechanical ventilation
   •   All deaths occurred in those with RNA-aemia
Tan et al., MedRxiv34 n=67, Chongqing, China    •  9/63 (14%) positive for RNA
Chen et al., MedRxiv35 n-97, Zhuhai, China    •  Whole blood: 4/97 
   •  All 4 patients with RNA-aemia had the lowest oxygenation
Bouadma et al., 
MedRxiv36
n=1, Paris, France    •  Blood: 1/1 RNA detected 
   •  Patient developed multi-organ failure and died
CONVALESCENT PATIENTS (>28 days)
Ling et al. Chinese 
Med J37
n=14, convalescent patients    •  Serum: 0/14 (0%)
HEALTHY DONORS
Chang et al., Emerging 
Infectious Diseases38
n= 7425 Healthy blood donors, Wuhan 
Blood Center, China. Collected Jan-March 
2020, peak epidemic.
   •   Prospective testing of 1,656 platelet donations and 774 
whole blood donations: 1/2430 RNA positive (0.04%)
   •   Retrospective testing of whole blood donations: 3/4995 
RNA positive (0.1%)
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The assay demonstrated a 95% detection rate for 13 RNA 
copies of SARS-CoV-2 RNA transcript spanning the 
amplified region39.
•    Convalescent samples collected through NHSBT were 
analysed by Public Health England (Colindale), targeting 
either RdRp or a conserved region of the open reading 
frame (ORF1ab) gene of SARS CoV-2, together with 
detection of an assay internal control to monitor the 
extraction and RT-PCR processes. Reverse transcrip-
tion and PCR amplification was performed on an Applied 
Biosystems 7500 FAST system. Samples were aliquoted 
into lysis buffer containing an exogenously added internal 
control (soil-borne cereal mosaic virus (SBCMV) RNA 
transcripts40), prior to purification of nucleic acid. Total 
nucleic acid was extracted from samples using the 
Biomérieux NucliSENS easyMAG or eMAG system. 
Extracted nucleic acid was analysed by either an RT-PCR 
assay targeting the RDRP gene of SARS -2 CoV as previ-
ously described with minor modifications12 or a conserved 
region of the open reading frame (ORF1ab) gene. This assay 
uses the primers and probe sequences made public by CDC 
China41, together with detection of SBCMV IC. ORF1ab 
primers (100µM) were obtained from Metabion, Planegg, 
Germany, and ORF1ab probe (10µM) from Tib-Molbiol, 
Berlin, Germany. A 25µL RT-PCR reaction contained: 
5µL of RNA; 12.5µL of 2x reaction buffer; 0.4µL MgSO
4 
(50mM) provided with the Superscript III one step RT-PCR 
system with Platinum Taq Polymerase (Cat.11732088; 
Invitrogen, Darmstadt, Germany); 0.15µL ORF1ab-F; 
0.2µL ORF1ab-R; 0.125µL SBCMV-F; 0.5µL SBCMV-
R; 0.5µL ORF1ab-P; 0.125µL SBCMV-P; 1µL of reverse 
transcriptase/Taq mixture from the kit; 4.5µL molecular 
grade water. Thermal cycling was performed on an Applied 
Biosystems 7500 FAST system (Applied Biosystems, 
Thermo Fisher Scientific, Hemel Hempstead, England), 
as follows: 55°C for 10 minutes, 94°C for 3 minutes, 
45 cycles of 94°C for 15s, 58°C for 30 seconds.
High Ct values (>37.0) are often viewed as being non-specific in 
clinical diagnostic laboratories depending on the clinical situ-
ation. However, for research purposes we collected and reported 
all Ct values.
Viral culture system
For viral culture, we used 20 serum samples, designated VC01-20 
(identified in Underlying Data File 19). VC01-16 comprised 
acute and convalescent samples that were RT-PCR positive, 
selected at random from our sample bank, representing samples 
from 12 individual patients (four individuals were represented 
at two timepoints), collected at 3-20 days following onset of 
symptoms. VC17-20 were pre-pandemic control samples. One 
further sample collected from a pre-pandemic NHSBT serum 
donation was used as media (VC21).
Samples VC01-20 were provided blinded for viral culture experi-
ments. 50 µL aliquots of samples VC1-VC20 were separately 
added to 2.4 x 105 Vero E6 cells (Cell Bank, Sir William Dunn 
School of Pathology, University of Oxford) in 24 well plates. 
Cells were propagated in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% foetal bovine serum (FBS). 
Virus growth assays were done in DMEM supplemented with 
1% FBS, glutamine and penicillin/streptomycin, according to 
published methods42. In parallel, wells of the same number of 
cells were cultured in triplicate without virus challenge but 
with 50 µL control serum (VC21), or in duplicate with a 
stock of Victoria/01/2020 SARS-CoV-2 passage 4 (Oxford) at 
calculated ten-fold serial dilutions per well of 78, 7.8, 0.78 
and 0.078 plaque forming units (pfu) in 50 µL of control serum 
(VC21).
Wells were observed daily for cytopathic effects (CPE), using 
images to record all cultures on days 3 and 7 (electronically 
archived using LabArchives Research Notebook). We took 
50 µL samples for vRNA extraction on day 3 post-challenge. 
Where residual sample volumes permitted, 50 µL aliquots of 
the respective serum were processed in parallel. In addition, 
1 × 108 vRNA copies produced by in vitro transcription and quan-
tified by droplet digital PCR were spiked into two equivalent 
control media samples, and processed in parallel, to provide quan-
tification and estimate the loss of vRNA during extraction. All 
samples were processed for vRNA using QIAamp Viral RNA 
Mini kits according to the manufacturer’s instructions. RNA 
extracts were analysed by qRT-PCR, and vRNA copy number was 
interpolated from the standard curve of Ct value by known copy 
number. On day 4, 50 µL aliquots of supernatants from cells chal-
lenged with VC01-20 were “blind passaged” to fresh cells, and 
the remaining supernatants were harvested and stored separately 
at -80C for future analysis. After a further 3 days, we recorded 
CPE, if any, for second passage cultures.
RT-PCR of culture supernatant. To determine whether there 
had been productive infection of cells in vitro, we took aliq-
uots of culture supernatant, including positive and negative con-
trols, and serum samples for qRT-PCR analysis using CDC NP1, 
CDC NP2 and HKU ORF1b diagnostic panels.
For the CDC NP1 and NP2 assay, we used an N-gene dig-
ital droplet quantified in vitro transcribed RNA standard 
(GenExpress, Germany). For the HKU ORF1b assay, we used 
qRT-PCR quantified RNA extracts of Victoria/01/2020 
SARS-CoV-2 passage 4 (Oxford) as RNA standard, diluted to 
107 copies/reaction and preparing a serial dilution. We used 
Luna Universal Probe One-step qRT-PCR kit (New England 
Biolabs, USA) for all reactions following the manufacturer’s 
instructions, with either 5 µL or 2.5 µL RNA sample in a 20 µL 
or 10 µL reaction (see Table in Extended Data File 29). Primer 
and probe concentrations in reactions were as specified by 
guidelines from the CDC and University of Hong Kong for 
their respective assays. PCR cycle conditions were: 10 minutes 
at 55°C, 1 minute at 95°C, followed by 45 cycles of 5 seconds 
at 95°C and 30 seconds 55°C. We manually adjusted the 
threshold for all runs to 0.2 and qRT-PCR efficiency was 
calculated for quality control. We used slopes from RNA stand-
ard curves to interpolate vRNA copy numbers in samples. 
Samples were analysed in six qRT-PCR runs in total. Each 
Page 9 of 21
Wellcome Open Research 2020, 5:181 Last updated: 25 NOV 2020
qRT-PCR run contained a freshly prepared RNA standard dilu-
tion with a quantitative logarithmic range from 107 to 101 vRNA 
copies/reaction to calculate vRNA copy numbers across all 
samples.
Serological testing of serum samples for antibody to 
SARS-CoV-2
For a subset of clinical samples collected in Oxford 
(n=160), we determined an antibody titre using the Siemens 
SARS-CoV-2 Total (COV2T), Atellica Solution immunoassay 
analyser, at Public Health England Porton Down. This assay 
measures total antibody to Spike protein S1 Receptor Binding 
Domain (RBD). In a recent evaluation of performance, under-
taken collaboratively by Public Health England and Oxford 
University, this assay had a sensitivity of 98.1% (95% CI 96.6, 
99.1) and specificity 99.9% (95% CI 99.4, 100), making it 
the best performing of the commercially available platforms 
assessed43. The assay was undertaken at Public Health 
England, Porton Down, according to the manufacturer’s 
instructions, with a threshold of ≥1.0 standard units for 
calling a positive test.
Ethics
Acute hospital in-patients were recruited into the Sepsis 
Immunomics study (Ref: 19/SC/0296). Convalescent health-
care workers with hospital encounters (n=38) and convalescent 
patients (n=32) provided informed consent for recruitment into the 
ISARIC WHO Clinical Characterisation Protocol UK (ISARIC 
WHO CCP-UK), with ethics approval by the South Central 
(Oxford C) Research Ethics Committee in England (Ref: 13/
SC/0149), and Scotland A Research Ethics Committee in Scotland 
(Ref: 20/SS/0028). Additional convalescent healthcare workers 
were recruited by the Oxford GI Biobank, n=3 (approval by 
Yorkshire and The Humber - Sheffield Research Ethics 
Committee, ref. 16/YH/0247). Healthy pre-pandemic control 
samples were used under NHSBT ethics, providing donor 
consent for their anonymised samples to be used in research.
Statistical analysis
Anonymised data were stored using Microsoft Excel. We analysed 
and presented data using GraphPad Prism v.8.3.1. Statistical 
analyses were undertaken using R 3.6.2. Binomial confidence 
intervals are presented for proportions. Univariable and 
multivariable logistic regression models were used to determine 
associations between detectable vRNA and time since symptom 
onset, disease severity and patient sex and age, accounting 
for any non-linear effects of continuous factors using natural 
cubic splines. Meta-analysis was undertaken using the meta 
package for R, version 4.12.
Results
Literature review to determine the frequency and 
clinical associations of RNA-aemia
We identified 28 relevant studies (Table 1; Table S1), among 
which 22 contained metadata suitable for meta-analysis 
(Figure 1). Point estimates for the frequency of vRNA detection 
are presented for each study representing ≥5 individuals, together 
with 95% confidence intervals (Figure 2; Table S1). We observed 
considerable heterogeneity in the range of estimates for 
vRNA-aemia, from 0% in several studies21,23,25,26,37, up to 76% in a 
report of patients in a critical care setting18. Pooling the data from 
these reports, the point estimate for the prevalence of vRNA in 
blood products in the 28 days following symptomatic infection 
is 10% (95%CI 5-18%, random effects model).
Viral RNA-aemia was reported in association with more severe 
disease in some studies, including a higher risk of admission to 
critical care settings, and increased incidence of acute clinical 
deterioration14,16,17,27. One study reported lower RNA levels in serum 
compared to other sample sites3, whilst another found RNA 
levels in blood to be no different to that of other sample types4. 
In a small number of reports that included specific Ct values, 
these were typically high, although studies used variable PCR 
targets and different thresholds for reporting positivity (details 
of methods and reported Ct values are available in Table S2).
We excluded two studies from the meta-analysis because they 
focused on cohorts with different characteristics from all other 
sample sets. One of these reported PCR results from samples 
taken at timepoints beyond 28 days, among which none con-
tained vRNA37. The other investigated vRNA-aemia in healthy 
blood donors in Wuhan, China at the time of the peak of the 
local epidemic in the first three months of 2020, finding 
vRNA in six samples from among >7000 screened38.
Frequency and timing of SARS-CoV-2 RNA-aemia in a 
local cohort
Our local clinical sample set included n=212 samples from 
167 patients (median age 57 years, IQR 46-76), 89 male (53%). 
In 163 patients for whom clinical data were available, dis-
ease was classified as asymptomatic (n=1, 0.6%), mild (n=81, 
50.0%), severe (n=37, 22.7%), or critical (n=44, 27.0%). In this 
sample set, collected at a median of 11 days post symptom onset 
(IQR 7-17 days), 27/212 were PCR positive for vRNA (12.7%, 
95%CI 8.6-18.0%). Deduplicating this to represent 167 unique 
individuals, 20 (12.0%, 95%CI 7.5-17.9%) had RT-PCR 
positive serum at any time point tested. Considering all 212 
samples in a multivariable analysis, critical disease severity was 
associated with increased vRNA-aemia, comparing mild and 
asymptomatic cases to severe (OR 2.3, 95%CI 0.5-12.6, p=0.29) 
and critical cases (OR 7.5, 95%CI 2.0-37.3, p=0.006) (Table 2). 
Within this dataset there was moderate statistical evidence of a 
trend towards decreased odds of vRNA-aemia over time (OR, per 
day, 0.95, 95%CI 0.89-1.00, p=0.12) (Table 2; Figure 3).
Pooling our hospital data with results from the NHSBT conva-
lescent cohort, vRNA was detected in 23/131 (17.6%, 95%CI 
11.5-25.2) samples collected up to day 13, 4/40 samples from 
between day 14–27 (10.0%, 95%CI 2.8-23.7%), and 0/494 
samples at ≥28 days (0%, 95%CI 0.0-0.7%) (Figure 2B). Day 
20 was the latest time point at which any PCR positive sample 
was collected.
Ct values for all of our 27 PCR-positive sera were high (median 
40.9, range 33.6–44.8). Using the more stringent Ct threshold 
of 37 that may be applied by clinical laboratories to report 
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a positive result, only 7/25 fell below this cut off, reducing our 
overall positive rate to 7/212 among the local clinical cohort 
(3.3%, 95%CI 1.3-6.6%) or 7/674 across our entire sample set 
(1.04%, 95%CI 0.42-2.13%).
Cytopathic effects arise in cell cultures inoculated with 
reference viral stock, but not in samples from COVID-19 
patients or pre-pandemic controls
Healthy uninfected control cell cultures of Vero E6 cells were 
established (Figure 4A). We observed substantial cytopathic 
effects (CPE) in all samples inoculated with reference virus, 
characterised by cell rounding up and detaching (Figure 4B). 
CPE of this type was observed in wells challenged with 78 and 
7.8 pfu, and moderate but typical CPE was observed in one well 
challenged with calculated 0.78 pfu reference virus. Cells exposed 
to a 1/10 dilution of control plasma did not show typical viral 
CPE. However in contrast to the CPE seen with reference virus, 
these control samples, the VC01-20 test cultures, and the 
culture inoculated with 0.078 pfu, instead showed variable 
Figure 3. Relationship between RNA-aemia and days from COVID-19 symptom onset. Data shown for 212 samples collected from 
acute and convalescent adults from the Oxford University Hospitals cohort. Positive and negative results are shown plotted at 1 and 0 on 
the y-axis respectively, with jitter applied to show all points. The line shows the univariable predicted probability of RNA detection over time 
(95% CI: shaded).
Table 2. Odds ratios (OR) for associations between RNA-
aemia and other patient characteristics, among 212 adults 
with confirmed COVID-19 infection recruited at Oxford 
University Hospitals NHS Foundation Trust.
Clinical attribute Multivariable 
OR
95% CI P value
Age, per 10 years 0.97 0.74 1.29 0.85
Sex, Female 1.00 (reference)
Sex, Male 1.54 0.61 4.10 0.37
Severity, Mild or 
Asymptomatic
1.00 (reference)
Severity, Severe 2.31 0.51 12.64 0.29
Severity, Critical 7.46 2.02 37.31 0.006
Time from symptom 
onset, per day
0.95 0.89 1.00 0.12
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cellular abnormalities and noticeable gel-formation in most 
samples (Figure 4C). Second passage cultures were undertaken 
in all cases, and none showed evident cytopathic effects at day 7 
(Figure 4D). This approach is limited to the sample volume of 
50 µL but we have demonstrated a single pfu at this volume 
reliably. Our detection threshold is <20 pfu/mL plasma, suggesting 
that plasma samples contain <0.1 infectious unit per 50 µL.
RT-PCR of culture supernatant
To determine whether there had been productive infection of 
cells in vitro, we took aliquots of culture supernatant for RT-PCR. 
From the positive control cultures, any culture receiving ≥1 
infectious unit of virus (78 and 7.8 pfu in 50 µL of control serum) 
on day 0 produced ≥1 × 105 copies of viral RNA (vRNA) per 
sample by day 3, detected by all three (CDC NP1, CDC NP2 
and HKU ORF1b) primer/probe sets. All diagnostic panels also 
detected low levels of vRNA in the culture inoculated with a 
calculated dose of 0.078 pfu. These vRNA traces are likely to 
reflect fragments and RNA debris from the cells in which the 
virus was grown.
No serum sample, and no serum-inoculated cultures had >100 
vRNA copies by day 3 based on the CDC, NP1 and NP2 assays. 
Marginal vRNA was detected in 10 serum samples, but none 
Figure 4. Typical images from cell culture in an in vitro system for SARS-CoV-2 culture. Top row shows controls: (A) Negative control 
Vero E6 cells in media; (B) Cytopathic effect (CPE) in Vero E6 cells spiked with Victoria/01/2020 SARS-CoV-2; Bottom row shows Vero E6 cells 
inoculated with 1/10 dilution of serum sample from sample VC12 (patient ID UKCOV040), that tested positive for SARS-CoV-2 RNA by RT-
PCR; (C) Aberrant cellular effects at day 4 in a culture inoculated with VC12 at day 0; (D) Normal appearance of cells at day 7 inoculated with 
1/10 dilution of the culture supernatant of the VC12-challenged culture, illustrated in (C). Raw unedited microscope images can be accessed 
individually on line9.
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of these showed a rising titre by day 3 and none had vRNA 
levels within the reliably quantifiable range. The highest 
were in the range found in the sub-infectious dose positive 
control cultures (Extended Data File 29). In contrast, no vRNA 
copies could be detected in serum-inoculated cultures tested at 
day 3 using the HKU ORF1b primer/probe set, while for the 
majority of original sera samples the HKU ORF1b assay gave 
similar results to the CDC, NP1 and NP2 diagnostic panel. The 
only exception from this was VC15, where marginal vRNA 
was detected in both serum and serum-inoculated cultures. These 
results suggest that no rising titre or no vRNA can be detected in 
serum-inoculated cultures. The comparison between the CDC 
and HKU diagnostic panels highlights interesting differences for 
detection of SARS-CoV-2 virus and should be explored further.
Relationship between serum SARS-COV-2 RT-PCR and 
antibody titre
We derived SARS-CoV-2 antibody titres for 160 clinical sam-
ples using a commercial immunoassay (Siemens); raw data 
are available in Underlying Data File 1. The antibody test 
was positive in 100/160 (62.5%) of serum samples tested, and 
the rate of positivity was higher in PCR-negative compared to 
PCR-positive samples (p=0.019; Figure 5A). However, there 
was no quantitative difference in antibody titres according to 
the PCR-status of the sample (p=0.14; Figure 5B). Among 23 
PCR-positive serum samples, antibody titres varied across 
the dynamic range of the Siemens assay; in this small sam-
ple set, the absence of CPE in vitro was not dependent on the 
detection of total antibody  (Figure 5C).
Discussion
Impact of results
Recognition that SARS-CoV-2 RNA may be detected and 
quantified in blood highlights its potential provenance as a 
biomarker, but also raises concerns about safety for personnel 
handling samples in clinical and research environments. Protocols 
to underpin the safe handling of blood samples need to consider 
the best evidence for routes and risks of transmission in order to 
mandate safe laboratory practice, being informed by the nature 
of the samples and the specific task being undertaken (including 
any risk of aerosol generation), while also maintaining optimum 
cost effective workflow of clinical samples. Local risk assess-
ments may currently result in disparate protocols being established 
by different organisations, but risk assessments should be 
proportionate, and - as far as possible - unified, and evidence- 
based. Developing new data to support laboratory practice is an 
important foundation for standardising practical guidelines.
Based on a systematic review of the literature, together with 
our own data, we estimate that SARS-CoV-2 RNA may be 
present at low copy numbers in ~10% of blood samples obtained 
from individuals with COVID-19 prior to day 28, most of which 
arise at earlier timepoints and in the setting of more severe 
disease. Despite being PCR-positive for vRNA, none of our 
clinical samples exceeded the threshold for viral infectivity.
Relationship between viral load and disease phenotype
The Ct values reported in the literature and in our local samples 
are high, reflecting low copy numbers and suggesting that 
assays may be detecting genomic fragments rather than replica-
tion-competent virus in blood. However, it is also possible that 
intact virions are present, but that these are immune-complexed 
or otherwise neutralised, accounting for the lack of CPE in our 
culture system.
A previous study reported a decline in RNA-aemia in severe 
cases from 45% at the time of admission to 11% by week 4, 
and in mild cases from 27% to 0% over the same time period, 
although these differences did not reach statistical significance3. 
Viral load (measured by qRT-PCR) in respiratory samples has 
been correlated with disease severity3,44,45. Detection of vRNA in 
blood therefore may be more common in severe/critical disease as 
Figure 5. Relationship between serum SARS-COV-2 RT-PCR and total antibody titre, determined by Siemens SARS-CoV-2 Atellica 
assay.  (A) Proportion of samples testing antibody positive according to RT-PCR status of serum sample; p-value by Fisher’s Exact Test; 
(B) Distribution of IgG titres in samples according to RT-PCR status of serum sample; boxes show median/IQR and whiskers show range; 
p-value by Mann-Whitney U test; (C) Antibody titres in 23 serum samples testing RT-PCR positive for SARS-CoV-2 RNA, presented in 
rank order. The bars marked with an asterisk indicate the samples for which in vitro culture was attempted. In all panels, antibody 
positivity is reported according to the threshold set by the assay manufacturer.
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a result of higher viral loads overall, or specifically relating to a 
high burden of infection in the lungs leading to spill-over into the 
circulation, or reflecting the destruction of infected cells in the 
respiratory epithelium. Multisystem end-organ disease caused 
by SARS-CoV-2 could reflect systemic viral dissemination 
by blood or lymphatics (potentially with direct infection of lym-
phocytes), or may arise as a consequence of a sepsis syndrome 
triggered primarily by localised pulmonary infection46. Given 
the high Ct values for vRNA in blood, the identification of virus 
in the vascular compartment currently remains non-specific; 
further work is needed to understand its origins and signifi-
cance, and to determine whether vRNA in the blood is innocuous 
or could contribute to immune dysfunction and the systemic 
inflammatory process.
Further work is needed to determine the bioburden and clinical 
significance of SARS-CoV-2 in other tissue types, for example 
in faeces47,48. Different clinical and laboratory infection control 
practices should be considered for specific sample types, ide-
ally based on an understanding of the frequency and duration 
of carriage and assessment of whether infectious virus can be 
detected.
Relationship between antibody detection and RNA-
aemia
The relationship between RNA-aemia and antibody status 
may be a causal one, in which neutralising antibodies directly 
reduce viral titres in blood. However, this association may 
also be a feature of the time-course of evolving infection, as 
samples collected early in infection are both more likely to con-
tain a ‘spill over’ of virus from the respiratory tract into blood, 
and to be seronegative, reflecting a ‘window period’ before 
seroconversion6. We have not tested neutralising activity on 
this current sample set, but a number of studies now show 
a close association between IgG titres and neutralisa-
tion, which confirms the biological activity of the antibodies 
in vitro49,50, suggesting a causal association is entirely plau-
sible. It should also be noted that commercially available 
platforms for antibody testing are validated on the basis of 
reporting a binary read-out, based on positive/negative thresh-
olds set by the manufacturer, but neutralising antibodies may 
be present even below this threshold which could explain the 
lack of CPE even in samples for which the Siemens assay was 
reported as negative.
Caveats and limitations
Datasets reported in the literature represent mostly a small 
number of carefully selected patients, typically in the acute 
hospital setting and therefore biased towards inclusion of more 
unwell patients meeting WHO criteria for severe or critical disease. 
Recognising that the field that is currently moving at pace, we 
elected to include papers from the pre-print server MedRxiv, 
for which peer review has not been undertaken. As a result, not 
all material included has undergone this quality assurance step. 
Published reports frequently do not include timing of sample 
collection relative to diagnostic respiratory samples and/or 
symptom onset, samples from individuals with trivial or absent 
symptoms are not well represented in existing studies, and there 
are insufficient data to distinguish between frequency or quantifica-
tion of vRNA present in whole blood, versus serum or plasma.
Due to the logistics of rapid recruitment of different patient 
groups through different pathways, RT-PCR methods varied by 
cohort, potentially introducing some variation in the sensitiv-
ity of detection. In our clinical samples, we adopted an inclusive 
approach to reporting detection of vRNA, by including sam-
ples with Ct values above those which would normally be called 
positive by a clinical diagnostic facility. This may lead to an 
over-estimation of the true prevalence of RNA-aemia in this 
sample group. Many previous publications do not report Ct 
values and direct comparisons between datasets are therefore 
difficult.
The absence of CPE and amplification of vRNA must be con-
sidered within the constraints of the low sample volume (50 µL 
in each assay), and the limits of detection within the assays 
used. We tested serum samples after they had been subjected to 
a freeze/thaw cycle, which could also have potential influ-
ence on retrieval of infectious virus. However, as samples were 
frozen in accordance with standard laboratory operating proto-
cols within a few hours of collection, we anticipate this would 
have a limited impact on viral replication capacity, as has been 
demonstrated previously for other viruses51–53.
Conclusions
Our data confirm that blood from COVID-19 patients may 
contain detectable RNA, but this arises in a minority of samples 
and is typically in low copy numbers, often outside the thresh-
old that would be reported as positive in a clinical diagnostic 
laboratory. Based on evaluation of a small sample set, we have 
found no evidence to suggest that blood samples containing RNA 
could yield replication competent virus, suggesting a negligible 
risk of transmission of SARS-CoV-2 to healthcare workers 
and laboratory staff from handling such material. However, 
laboratory practice should be informed by guidance from Public 
Health England54, CDC55 and WHO56; individual risk assess-
ment is important to account for the nature of the material being 
handled and the process being undertaken. Universal precautions 
and routine safety procedures should be carefully observed, not 
only to protect from SARS-CoV-2 infection but also to provide 
protection from other potential pathogens. Further data are needed 
to determine the extent to which serum PCR positivity for 
vRNA is useful as a diagnostic or prognostic marker in patients 
with COVID-19 infection.
Data availability
Underlying data
Figshare: SARS-CoV-2 RNA in blood. https://doi.org/10.6084/
m9.figshare.12278249.v89.
This project contains the following underlying data:
-     Underlying Data File 1.xlsx (Metadata table for serum 
samples from adults with confirmed SARS-CoV-2 
infection, based on RT-PCR nose/throat swab and/or 
EuroImmun antibody titre)
 Sheet 1: samples obtained through patients recruited into a 
UK clinical cohort at Oxford University Hospitals NHS Foun-
dation Trust (n=212 samples from 167 unique individuals). 
Cells highlighted in blue show follow-up samples collected 
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References
from the same individual at different time points. Cells 
highlighted in orange show serum PCR positives. All indi-
viduals had a diagnosis based on an RT-PCR throat swab 
positive for SARS-CoV-2. Sheet 2: samples obtained from 
convalescent donors a minimum of 28 days post resolution 
of symptoms, via NHS Blood and Transplant, NHSBT 
(n=142 samples from 142 individuals).
-     Fig 4A 20200501_cc1.jpg (raw unedited microscope 
images for Figure 4A)
-     Fig 4B 20200501_1in100_2.jpg (raw unedited microscope 
images for Figure 4B)
-     Fig 4C 20200501_vc12.jpg (raw unedited microscope 
images for Figure 4C)
-     Fig 4D 20200504_vc12.jpg (raw unedited microscope 
images for Figure 4D)
Extended data
Figshare: SARS-CoV-2 RNA in blood. https://doi.org/10.6084/
m9.figshare.12278249.v89.
This project contains the following extended data:
-     Extended Data File 1.xlsx (Metadata table providing 
data for prevalence of SARS-CoV-2 RNA in blood and 
blood products based on a systematic literature review. 
Details of 28 citations are presented, and the 22 
studies included in quantitative meta-analysis are 
indicated)
-     Extended Data File 2.pdf (qRT-PCR quantification of 
vRNA from sera and viral culture assays. Calculation 
of vRNA copy numbers, and qRT-PCR results in figure 
and table format.)
-     RT-PCR Primer sequences.xlsx (Primer sequences)
Reporting guidelines
Figshare: PRISMA and STROBE checklists for ‘SARS-CoV-2 
RNA detected in blood products from patients with 
COVID-19 is not associated with infectious virus’ https://doi.
org/10.6084/m9.figshare.12278249.v89.
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